These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23354833)

  • 1. Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
    Nagane M; Kobayashi K; Tanaka M; Tsuchiya K; Shishido-Hara Y; Shimizu S; Shiokawa Y
    Int J Clin Oncol; 2014 Feb; 19(1):16-23. PubMed ID: 23354833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and daily temozolomide for recurrent glioblastoma.
    Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
    Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
    Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
    Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
    Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
    Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
    Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
    Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
    Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
    Omuro A; Beal K; Gutin P; Karimi S; Correa DD; Kaley TJ; DeAngelis LM; Chan TA; Gavrilovic IT; Nolan C; Hormigo A; Lassman AB; Mellinghoff I; Grommes C; Reiner AS; Panageas KS; Baser RE; Tabar V; Pentsova E; Sanchez J; Barradas-Panchal R; Zhang J; Faivre G; Brennan CW; Abrey LE; Huse JT
    Clin Cancer Res; 2014 Oct; 20(19):5023-31. PubMed ID: 25107913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
    Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
    J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
    Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
    J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.
    Jain R; Scarpace LM; Ellika S; Torcuator R; Schultz LR; Hearshen D; Mikkelsen T
    J Neurooncol; 2010 Feb; 96(3):423-31. PubMed ID: 19859666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab is active as a single agent against recurrent malignant gliomas.
    Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
    Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
    Reardon DA; Desjardins A; Peters K; Gururangan S; Sampson J; Rich JN; McLendon R; Herndon JE; Marcello J; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2011 Jun; 103(2):371-9. PubMed ID: 20853132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
    Korones DN; Smith A; Foreman N; Bouffet E
    Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
    Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.